Literature DB >> 12397840

The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series.

Thomas L Schwartz1.   

Abstract

Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12397840

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


  8 in total

Review 1.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

2.  Tiagabine may reduce bruxism and associated temporomandibular joint pain.

Authors:  R E Kast
Journal:  Anesth Prog       Date:  2005

3.  Management of treatment-resistant panic disorder.

Authors:  Richard L Holt; R Bruce Lydiard
Journal:  Psychiatry (Edgmont)       Date:  2007-10

Review 4.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

5.  Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines.

Authors:  John Huh; Deborah Goebert; Junji Takeshita; Brett Y Lu; Mark Kang
Journal:  Prim Care Companion CNS Disord       Date:  2011

6.  Low-dose tiagabine effectiveness in anxiety disorders.

Authors:  James L Schaller; John Thomas; David Rawlings
Journal:  MedGenMed       Date:  2004-09-17

Review 7.  Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Authors:  Peter Zwanzger; Rainer Rupprecht
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.